Abio Materials key facts
- Developer of bioactive cosmetic and medical products designed to utilize exosome-based compounds for regenerative applications.
- It has raised $8.6M; the latest was Later Stage VC ($5.4M) in Aug 2025.
- Notable investors include IMM Investment, Korea Technology Finance, Lotte Ventures, IBK Securities, JB Investment (Private Equity) — 13 tracked in total.
- Status: Privately Held (backing).
Who backs Abio Materials
13+- ·The complete investor list: 13 names
- ·Watch Abio Materials: the Monday email on marks, rounds and moves
Abio Materials funding rounds
No funding rounds for Abio Materials are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Abio Materials investors
13 investors are on record for Abio Materials, including IMM Investment, Korea Technology Finance, Lotte Ventures and IBK Securities.
About Abio Materials
Developer of bioactive cosmetic and medical products designed to utilize exosome-based compounds for regenerative applications. The company offers formulations derived from plant, human, and microbial exosomes that support cell signaling, inflammation reduction, and collagen synthesis, enabling skincare and medical device manufacturers to create clinically validated products that promote tissue regeneration, enhance skin health, and deliver targeted therapeutic benefits.
- Sector
- Healthcare
- HQ
- Yongin, South Korea
- Founded
- 2020
- Employees
- 69
- Website
- a-bio.co.kr/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Abio Materials doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.